Next Article in Journal
Novel ACE Inhibitory Peptides Derived from Simulated Gastrointestinal Digestion in Vitro of Sesame (Sesamum indicum L.) Protein and Molecular Docking Study
Next Article in Special Issue
Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer
Previous Article in Journal
Defeating Antibiotic-Resistant Bacteria: Exploring Alternative Therapies for a Post-Antibiotic Era
Previous Article in Special Issue
Analysis of the Molecular Signaling Signatures of Muscle Protein Wasting Between the Intercostal Muscles and the Gastrocnemius Muscles in db/db Mice
Open AccessReview

Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?

Institute of Oncology Research, Faculty of Biomedical Sciences, USI, 6500 Bellinzona, Switzerland
Department of Health Sciences, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, Italy
Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland
Faculty of Biomedical Sciences, USI, 6900 Lugano, Switzerland
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(3), 1060;
Received: 21 January 2020 / Revised: 31 January 2020 / Accepted: 3 February 2020 / Published: 5 February 2020
(This article belongs to the Special Issue mTOR in Human Diseases 2.0)
The activation of the PI3K/AKT/mTOR pathway is a main driver of cell growth, proliferation, survival, and chemoresistance of cancer cells, and, for this reason, represents an attractive target for developing targeted anti-cancer drugs. There are plenty of preclinical data sustaining the anti-tumor activity of dual PI3K/mTOR inhibitors as single agents and in combination in lymphomas. Clinical responses, including complete remissions (especially in follicular lymphoma patients), are also observed in the very few clinical studies performed in patients that are affected by relapsed/refractory lymphomas or chronic lymphocytic leukemia. In this review, we summarize the literature on dual PI3K/mTOR inhibitors focusing on the lymphoma setting, presenting both the three compounds still in clinical development and those with a clinical program stopped or put on hold. View Full-Text
Keywords: TORC1; TORC2; PI3K; lymphoma; chronic lymphocytic leukemia TORC1; TORC2; PI3K; lymphoma; chronic lymphocytic leukemia
Show Figures

Graphical abstract

MDPI and ACS Style

Tarantelli, C.; Lupia, A.; Stathis, A.; Bertoni, F. Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma? Int. J. Mol. Sci. 2020, 21, 1060.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop